Pacira Pharmaceuticals, Inc. (PCRX): Laura Brege , director of Pacira Pharmaceuticals, Inc. sold 1,000 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $46.95 per share for a total value of $46,950.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 8, 2016, Kristen Marie Williams (CAO and General Counsel) sold 600 shares at $47.20 per share price.On Jun 8, 2016, Mark A. Kronenfeld (director) sold 900 shares at $46.95 per share price.Also, On Jun 8, 2016, Paul J Hastings (director) sold 1,136 shares at $46.95 per share price.On Apr 19, 2016, David M Stack (CEO and Chairman) sold 25,000 shares at $64.29 per share price.
Shares of Pacira Pharmaceuticals Inc (PCRX) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.21 points or -0.43% at $48.19 with 4,64,196 shares getting traded. Post opening the session at $47.93, the shares hit an intraday low of $46.91 and an intraday high of $48.37 and the price vacillated in this range throughout the day. The company has a market cap of $1,791 M and the number of outstanding shares has been calculated to be 3,71,67,255 shares. The 52-week high of Pacira Pharmaceuticals Inc is $80.992 and the 52-week low is $35.78.
Company has been under the radar of several Street Analysts.Pacira Pharmaceuticals Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 105 from a previous price target of $113 . The Rating was issued on May 25, 2016.Pacira Pharmaceuticals Inc is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 64 from a previous price target of $71 . The Rating was issued on May 3, 2016.Pacira Pharmaceuticals Inc is Initiated by Mizuho to Buy and the brokerage firm has set the Price Target at $79. The Rating was issued on Apr 19, 2016.
Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.